新着情報

印刷

  • HOME
  • 新着情報
  • 【がん研セミナー(11月6日)のお知らせ「Functions of Transcription Factors BCL11A and BCL11B Connect Development and Cancer」Pentao Liu 博士(Wellcome Trust Sanger Institute, Cambridge, United Kingdom)】

新着情報

【がん研セミナー(11月6日)のお知らせ「Functions of Transcription Factors BCL11A and BCL11B Connect Development and Cancer」Pentao Liu 博士(Wellcome Trust Sanger Institute, Cambridge, United Kingdom)】

2014年10月27日

がん研セミナー(11月6日)のお知らせ

 

演題:Functions of Transcription Factors BCL11A and BCL11B Connect Development and Cancer

 

演者:Pentao Liu 博士(Wellcome Trust Sanger Institute, Cambridge, United Kingdom

 

日時:2014 116日(木)11:00-12:00

 

場所:吉田講堂

 

連絡先:中村卓郎(内線5391

 

抄録: 

BCL11A and BCL11B are two C2H2 zinc finger transcription factors. The two genes are being found to be involved in a number of normal developmental processes and in diseases. Bcl11a has critical functions in lymphopoiesis, in hematopoietic stem cells and in mammary epithelial stem cells. Bcl11a negatively regulates p53 via Mdm2 and transcriptionally controls several other pathways. In breast cancer, BCL11A gene is highly expressed in the majority of triple negative breast cancer (TNBC) and the locus is amplified in up to 30% of the cases. Experimental manipulation of BCL11A expression confirms that high levels of BCL11A are necessary and sufficient to transform immortalized breast epithelial cells, whereas its knockdown severely decreases tumorigenic potential of TNBC cells in xenograft models.

In a DMBA-induced mammary tumour model, Bcl11a is required in both tumour initiation and progression as no tumours form when Bcl11a is deleted prior to carcinogen treatment, and tumours regress when Bcl11a is inactivated in developing tumours. Bcl11b is only expressed in T lymphocytes in hematopoietic lineages. Bcl11b deletion in T cells causes loss of T cell identity, which leads to reprogramming of T cells to a new type of killer cells. The new killer cells are able to eliminate cancer cells in vitro with 100% efficiency, and thus provide an opportunity to probe genetic mechanisms whereby cancer cells become resistant to immune cell attacks. I will lastly describe a concept that connects iPSC pluripotency or totipotency to cancer cells and chemotherapies.

 

*外部の研究者のご来聴を歓迎いたします。尚、本セミナーの内容は専門的であり、医学・生物分野の研究に携わる方を対象としております。

このページのTOPへ